Exjade Related Published Studies
Well-designed clinical trials related to Exjade (Deferasirox)
Deferasirox reduces iron overload significantly in nontransfusion-dependent
thalassemia: 1-year results from a prospective, randomized, double-blind,
placebo-controlled study. [2012]
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a
randomized, double-blinded, placebo-controlled trial. [2012]
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. [2011.09.20]
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. [2011.08]
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. [2011.07.28]
[Curative effects and safety of deferasirox in treatment of iron overload in children with beta-thalassemia major]. [2011.07]
Effect of deferasirox on iron absorption in a randomized, placebo-controlled, crossover study in a human model of acute supratherapeutic iron ingestion. [2011.07]
Deferasirox does not induce QT/QTc-prolongation in healthy subjects. [2009.05]
Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. [2008.10]
Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. [2008.08]
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. [2008.06]
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. [2008.04]
Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. [2008.02]
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. [2008]
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. [2007.05]
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. [2006.12]
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. [2006.10]
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. [2006.07]
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. [2006.05.01]
Well-designed clinical trials possibly related to Exjade (Deferasirox)
Risk factors for mortality in patients with mucormycosis. [2012]
Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. [2005]
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. [2003.06]
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. [2003.05.10]
Other research related to Exjade (Deferasirox)
Approaching low liver iron burden in chelated patients with
non-transfusion-dependent thalassemia: the safety profile of deferasirox. [2014]
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell
disease: two-year results including pharmacokinetics and concomitant hydroxyurea. [2013]
Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy. [2011.11.20]
Importance of optimal dosing >/= 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with beta-thalassaemia. [2011.10]
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. [2011.10]
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. [2011.09]
The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major. [2011.09]
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. [2011.07]
Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil. [2011.06]
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. [2011.06]
Long-Term Efficacy of Deferasirox in Preventing Cardiovascular Complications in the Iron-Overloaded Gerbil. [2011.05.18]
Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. [2011.05]
Iron chelation adherence to deferoxamine and deferasirox in thalassemia. [2011.05]
Is deferasirox implicated in multiple organ failure in a patient with homozygous beta-thalassemia? [2011.05]
Chelation of cadmium by combining deferasirox and deferiprone in rats. [2011.05]
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. [2011.05]
Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. [2011.05]
Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. [2011.04]
Reversible Fanconi syndrome in a pediatric patient on deferasirox. [2011.04]
The effects of deferasirox on renal, cardiac and hepatic iron load in patients with beta-thalassemia major: preliminary results. [2011.04]
Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient. [2011.03]
Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. [2011.03]
Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. [2011.03]
Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia. [2011]
A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient. [2011]
Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia. [2011]
Safety and efficacy of deferasirox in multitransfused Indian children with beta-thalassaemia major. [2011]
[A 3-year clinical trial of deferasirox in heavily iron-overloaded patients with Beta-thalassemia major.] [2010.12]
[Deferasirox--a new oral iron chelator--review]. [2010.10]
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. [2010.09]
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. [2010.09]
Deferasirox for managing transfusional iron overload in people with sickle cell disease. [2010.08.04]
Deferasirox--current knowledge and future challenges. [2010.08]
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. [2010.07.29]
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. [2010.07]
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. [2010.07]
Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. [2010.05]
Gastric ulcer in a child treated with deferasirox. [2010.04]
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. [2010.04]
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. [2010.03.25]
Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. [2010.03.15]
Deferasirox: oral, once daily iron chelator--an expert opinion. [2010.02]
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. [2010.02]
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. [2010.02]
Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. [2010.01]
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. [2010]
Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. [2010]
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. [2010]
Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy. [2010]
A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea. [2009.11]
Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. [2009.11]
Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. [2009.09]
Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. [2009.08]
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. [2009.07]
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. [2009.06]
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. [2009.06]
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. [2009.05]
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. [2009.05]
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. [2009.05]
Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. [2009.05]
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study. [2009.04]
Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia. [2009.03]
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. [2009.01]
Deferasirox: an update. [2009]
Deferasirox (Exjade) for the treatment of iron overload. [2009]
Long-term efficacy and safety of deferasirox. [2008.12]
Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction. [2008.12]
Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. [2008.12]
Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. [2008.10]
Acute interstitial nephritis due to deferasirox: a case report. [2008.10]
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. [2008.09]
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. [2008.09]
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. [2008.07]
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. [2008.06]
Clinical application of deferasirox: practical patient management. [2008.05]
Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. [2008.05]
Patient-Reported Outcomes of Deferasirox (Exjade(R), ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Substudy of a Randomized Open-Label Phase II Trial. [2008.04.11]
Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. [2008.02]
|